ARWR falls after first human results for ARO-DIMER-PA
Arrowhead Pharmaceuticals shares fell over 10% on Tuesday after posting first human results for experimental ARO-DIMER-PA, a shot intended to silence two cholesterol genes with one molecule.
Shares of Arrowhead Pharmaceuticals (ARWR) fell over 10% on Tuesday after the company posted the first human results for ARO-DIMER-PA, an experimental shot designed to silence two cholesterol genes with one molecule. ARWR had already run hard into the catalyst and remains far above last year’s levels.